Ribociclib
- TRADE NAME: Kisqali (Novartis)
- INDICATIONS: Treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor)
- CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor
- HALF-LIFE: 30–55 hours
FDA APPROVAL DATE: 03/13/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alfentanil, Amiodarone, Bepridil, Boceprevir, Chloroquine, Clarithromycin, Conivaptan, Cyclosporine, CYP3A4 substrates, Dihydroergotamine, Disopyramide, Ergotamine, Everolimus, Fentanyl, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Methadone, Midazolam, Moxifloxacin, Ondansetron, Pimozide, Procainamide, QT prolonging drugs, Quinidine, Rifampin, Ritonavir, Saquinavir, Sirolimus, Sotalol, Strong CYP3A4 inducers and inhibitors, Tacrolimus, Voriconazole
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 08/02/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
